Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Blepharitis
Interventions: AzaSite®; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Lewiston, Maine • Andover, Massachusetts

Conditions: Eating Disorders, Body Dissatisfaction
Interventions: Pregnant Body Project (PBP), Pregnancy Health Education (PHE); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Cetaphil Restoraderm, Standard of Care; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 3 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Substance Abuse, Substance Addiction, Substance Use Disorder (SUD), Substance Use (Drugs, Alcohol), Human Immunodeficiency Virus (HIV)
Interventions: The TLC Program; Behavioral
Lead sponsor: Illinois Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Anti-CD20 (rituximab), Placebo Comparator; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Moderate Hypertriglyceridemia.
Interventions: Omega 3 fatty acid (Lovaza); Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Bupropion 150 mg XL, Placebo; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 362
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 262 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Maridebart cafraglutide, Semaglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Miami Lakes, Florida + 4 more

Conditions: Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions: ABBV-253; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas

Conditions: Psychotic Disorders
Interventions: Acceptance and Commitment Therapy, Treatment as Usual (TAU); Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: PostTraumatic Stress Disorder, Sleep Disorder, Stress Disorder, Sleep Initiation and Maintenance Disorders, Combat Disorders, Nightmares Associated With Chronic Post-Traumatic Stress Disorder, Nightmare, Nightmares, REM-Sleep Type
Interventions: NightWare Therapeutic System; Device
Lead sponsor: NightWare; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cataract
Interventions: Clareon; Device
Lead sponsor: Gainesville Eye Associates; Other
Eligibility: 50 Years and older
Enrollment: 31 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Georgia

Conditions: Chronic Kidney Disease, End-stage Renal Disease, Metabolic Acidosis
Interventions: Low Bicarbonate; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Multiple Myeloma
Interventions: SLAMF7 FPBMC; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Benign Prostatic Hyperplasia
Interventions: Optilume® BPH Catheter System; Device
Lead sponsor: Urotronic Inc.; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 7
States / cities: Little Rock, Arkansas • Tampa, Florida • Shreveport, Louisiana + 4 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 17
States / cities: La Jolla, California • San Diego, California • Walnut Creek, California + 13 more

Conditions: Chronic Fatigue Syndrome (CFS)
Interventions: Placebo condition, Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.; Dietary Supplement
Lead sponsor: Fred Friedberg; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: biologic sample preservation procedure, biopsy; Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Mental Health, Cultural Adaptation, Psychotherapy, Mood Disorders, Culturally Responsive Care, Asian, Digital Health Intervention
Interventions: Culturally-attuned digital tools; Other
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Multiple Myeloma
Interventions: Infusion of MCARH109 T cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Mild Cognitive Impairment, Mild Alzheimer's Disease
Interventions: PET scan & fMRI; Other
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 55 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Diabetes
Interventions: Application Validation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Communication Disorders, Developmental Disabilities
Interventions: Milieu Communication Teaching; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 18 Months to 27 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Kansas City, Kansas • Nashville, Tennessee

Search by objective public record fields.

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

Preventing Disordered Eating and Body Dissatisfaction Among High-risk Pregnant Individuals

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

The Trans-Led Care Study

Rituximab in New Onset Type 1 Diabetes

Lovaza Mechanisms of Action

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis

NightWare Open Enrollment Study

Evaluation of Binocular Visual Acuity and Refractive Stability in the Alcon Clareon Intraocular Lens

Comparison of High Versus Low Bicarbonate Hemodialysis

Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Tissue Sample Collection From Patients With Fanconi Anemia

Digital Mental Health for Asian Americans

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

Early Detection of Mild Cognitive Impairment in Individual Patients

Validation of the Diabetes Deep Neural Network Score for Diabetes Mellitus Screening

Effects of Intensity of Early Communication Intervention